Curanex Pharmaceuticals transitioned in 2023 from selling health supplements to focusing exclusively on the clinical-stage development of Phyto-N, a botanical drug candidate targeting ulcerative colitis. The company currently operates without revenue, relying heavily on external financing to fund costly FDA-required studies and planned clinical trials. Its intellectual property portfolio includes provisional patents and a PCT filing, but botanical drug development inherently faces complex regulatory and patent uncertainties. Capital requirements exceeding $150 million through approval present significant risks alongside dependencies on third-party manufacturing and clinical success.